Sernova (TSE:SVA) Trading Up 5.3% - Here's Why

Key Points

• Sernova Corp. (TSE:SVA) shares rose by 5.3% during trading, reaching a price of C$0.20, with increased trading volume of approximately 189,238 shares.
• The company operates in the regenerative medicine sector, developing bio-hybrid organs that integrate living cells with non-living materials to enhance organ function.
• Sernova has a market capitalization of C$67.30 million and a concerning price-to-earnings ratio of -1.93, indicating potential financial challenges.

Sernova Corp. (TSE:SVA - ) shares were up 5.3% during trading on Wednesday . The company traded as high as C$0.20 and last traded at C$0.20. Approximately 189,238 shares were traded during mid-day trading, an increase of 38% from the average daily volume of 136,995 shares. The stock had previously closed at C$0.19.

Sernova Stock Up 5.3%

The company has a current ratio of 0.32, a quick ratio of 18.11 and a debt-to-equity ratio of -4.40. The firm's 50 day moving average price is C$0.17 and its two-hundred day moving average price is C$0.19. The company has a market capitalization of C$67.30 million, a price-to-earnings ratio of -1.93 and a beta of 1.35.

About Sernova

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a bio-hybrid organ. A bio-hybrid organ refers to a medical device designed to be implanted into the human body, where it integrates with existing living tissue to replicate or enhance the function of a natural organ, essentially aiming to restore normal organ function by combining living cells with non-living materials to mimic the properties of the original organ and seamlessly interact with surrounding tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.